Ophthalmology · Phase 2-3 · pulled 2026-11-06

Age-related macular degeneration: trial sites and investigators

25 sites and 10 investigators from 219 completed and terminated Phase 2-3 trials of age-related macular degeneration (last 12 years), plus 133 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Age-related macular degeneration: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	Austin Retina Associates Austin, United States · 17 spellings merged	42 31 completed, 11 terminated	NCT05230537 NCT04567303 NCT05839041 6 trials with titles NCT05230537 A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration completed 2026-09-30 NCT04567303 Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration completed 2026-08-25 NCT05839041 A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) completed 2026-02-18 NCT07214740 Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe completed 2025-12-12 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT05536297 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy completed 2025-04-10	2026-09-30	25 NCT06087458 NCT06556368 NCT06541704 NCT07705555	89
2	Sierra Eye Associates Reno, United States · 2 spellings merged	42 33 completed, 9 terminated	NCT04567303 NCT06116890 NCT05811351 6 trials with titles NCT04567303 Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration completed 2026-08-25 NCT06116890 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration completed 2026-07-01 NCT05811351 A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) completed 2026-02-23 NCT05839041 A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) completed 2026-02-18 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT05536297 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy completed 2025-04-10	2026-08-25	16 NCT06635148 NCT03683251 NCT06864988 NCT07215234	89
3	Retinal Research Institute, LLC Phoenix, United States · 7 spellings merged	36 29 completed, 7 terminated	NCT05811351 NCT04770545 NCT03364153 6 trials with titles NCT05811351 A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) completed 2026-02-23 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT03364153 Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1) completed 2025-03-31 NCT05697809 Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema completed 2024-12-05 NCT05891548 Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration completed 2024-08-20 NCT04566445 HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 terminated 2024-06-10 Stop reason on the record: “Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns.”	2026-02-23	6 NCT06541704 NCT03683251 NCT06668064 NCT07215390	90
4	Southeast Retina Center Augusta, United States · 7 spellings merged	35 27 completed, 8 terminated	NCT04567303 NCT06116890 NCT05839041 6 trials with titles NCT04567303 Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration completed 2026-08-25 NCT06116890 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration completed 2026-07-01 NCT05839041 A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) completed 2026-02-18 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT05536297 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy completed 2025-04-10 NCT04740671 A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD completed 2024-12-31	2026-08-25	14 NCT06556368 NCT06541704 NCT03683251 NCT06864988	90
5	Retina Consultants of Texas The Woodlands, United States · 16 spellings merged	33 25 completed, 8 terminated	NCT06664502 NCT06116890 NCT05811351 6 trials with titles NCT06664502 A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration completed 2026-08-11 NCT06116890 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration completed 2026-07-01 NCT05811351 A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) completed 2026-02-23 NCT05839041 A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) completed 2026-02-18 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT05536297 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy completed 2025-04-10	2026-08-11	24 NCT06556368 NCT06541704 NCT06635148 NCT03683251	89
6	Cumberland Valley Retina Consultants Hagerstown, United States · 14 spellings merged	29 24 completed, 5 terminated	NCT04567303 NCT05811351 NCT05839041 6 trials with titles NCT04567303 Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration completed 2026-08-25 NCT05811351 A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) completed 2026-02-23 NCT05839041 A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) completed 2026-02-18 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT05536297 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy completed 2025-04-10 NCT06011798 Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) completed 2025-04-08	2026-08-25	27 NCT06556368 NCT06541704 NCT07705607 NCT06635148	90
7	Retina Research Institute of Texas Abilene, United States · 11 spellings merged	29 25 completed, 4 terminated	NCT06664502 NCT06116890 NCT05811351 6 trials with titles NCT06664502 A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration completed 2026-08-11 NCT06116890 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration completed 2026-07-01 NCT05811351 A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) completed 2026-02-23 NCT05839041 A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) completed 2026-02-18 NCT05536297 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy completed 2025-04-10 NCT05536752 QA102 Phase II Study in Subjects With Dry AMD completed 2024-11-12	2026-08-11	18 NCT06556368 NCT06541704 NCT06864988 NCT07205887	91
8	Black Hills Regional Eye Institute Rapid City, United States · 5 spellings merged	29 24 completed, 5 terminated	NCT06116890 NCT04770545 NCT05536297 6 trials with titles NCT06116890 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration completed 2026-07-01 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT05536297 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy completed 2025-04-10 NCT04777201 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration completed 2024-09-03 NCT04423718 Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye completed 2024-08-07 NCT04690556 Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD completed 2024-05-31	2026-07-01	7 NCT06087458 NCT06541704 NCT06864988 NCT07064759	91
9	Ophthalmic Consultants of Boston Boston, United States · 6 spellings merged	29 23 completed, 6 terminated	NCT05811351 NCT05839041 NCT04770545 6 trials with titles NCT05811351 A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) completed 2026-02-23 NCT05839041 A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) completed 2026-02-18 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT05536297 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy completed 2025-04-10 NCT03364153 Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1) completed 2025-03-31 NCT05893537 Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). terminated 2025-03-28 Stop reason on the record: “The trial was closed as part of a strategic business decision.”	2026-02-23	16 NCT06087458 NCT06556368 NCT06635148 NCT03683251	92
10	Northern California Retina Vitreous Associates Mountain View, United States · 12 spellings merged	28 20 completed, 8 terminated	NCT06664502 NCT05839041 NCT04770545 6 trials with titles NCT06664502 A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration completed 2026-08-11 NCT05839041 A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) completed 2026-02-18 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT05536752 QA102 Phase II Study in Subjects With Dry AMD completed 2024-11-12 NCT04777201 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration completed 2024-09-03 NCT05891548 Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration completed 2024-08-20	2026-08-11	9 NCT06541704 NCT06864988 NCT07205887 NCT07064759	87
11	Retina-Vitreous Associates Medical Group Beverly Hills, United States · 8 spellings merged	28 20 completed, 8 terminated	NCT06116890 NCT05839041 NCT06011798 6 trials with titles NCT06116890 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration completed 2026-07-01 NCT05839041 A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) completed 2026-02-18 NCT06011798 Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) completed 2025-04-08 NCT04566445 HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 terminated 2024-06-10 Stop reason on the record: “Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns.” NCT04690556 Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD completed 2024-05-31 NCT04603937 A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) terminated 2023-08-31 Stop reason on the record: “Study did not meet primary endpoint”	2026-07-01	14 NCT06541704 NCT05608837 NCT03683251 NCT06864988	91
12	Retina Specialty Institute Pensacola, United States · 2 spellings merged	27 21 completed, 6 terminated	NCT05811351 NCT05839041 NCT04770545 6 trials with titles NCT05811351 A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) completed 2026-02-23 NCT05839041 A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) completed 2026-02-18 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT03364153 Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1) completed 2025-03-31 NCT05536752 QA102 Phase II Study in Subjects With Dry AMD completed 2024-11-12 NCT04777201 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration completed 2024-09-03	2026-02-23	10 NCT06635148 NCT03683251 NCT06864988 NCT07064759	90
13	Retina Consultants of Orange County Fullerton, United States · 3 spellings merged	26 19 completed, 7 terminated	NCT05230537 NCT05811351 NCT04770545 6 trials with titles NCT05230537 A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration completed 2026-09-30 NCT05811351 A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) completed 2026-02-23 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT05536297 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy completed 2025-04-10 NCT04740671 A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD completed 2024-12-31 NCT05891548 Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration completed 2024-08-20	2026-09-30	8 NCT06556368 NCT06541704 NCT06635148 NCT07064759	87
14	Tennessee Retina PC Nashville, United States · 7 spellings merged	26 20 completed, 6 terminated	NCT04567303 NCT06664502 NCT05839041 6 trials with titles NCT04567303 Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration completed 2026-08-25 NCT06664502 A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration completed 2026-08-11 NCT05839041 A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) completed 2026-02-18 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT05893537 Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). terminated 2025-03-28 Stop reason on the record: “The trial was closed as part of a strategic business decision.” NCT04777201 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration completed 2024-09-03	2026-08-25	20 NCT06541704 NCT03683251 NCT07205887 NCT07064759	92
15	Retina Consultants San Diego Poway, United States · 5 spellings merged	26 18 completed, 8 terminated	NCT05811351 NCT04770545 NCT04777201 6 trials with titles NCT05811351 A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) completed 2026-02-23 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT04777201 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration completed 2024-09-03 NCT05891548 Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration completed 2024-08-20 NCT04423718 Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye completed 2024-08-07 NCT04566445 HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 terminated 2024-06-10 Stop reason on the record: “Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns.”	2026-02-23	11 NCT06087458 NCT06541704 NCT06635148 NCT03683251	88
16	Strategic Clinical Research Group, LLC Willow Park, United States · 4 spellings merged	25 21 completed, 4 terminated	NCT06116890 NCT05811351 NCT05536297 6 trials with titles NCT06116890 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration completed 2026-07-01 NCT05811351 A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) completed 2026-02-23 NCT05536297 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy completed 2025-04-10 NCT03364153 Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1) completed 2025-03-31 NCT04777201 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration completed 2024-09-03 NCT04611152 A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) terminated 2023-08-31 Stop reason on the record: “Study did not meet primary endpoint”	2026-07-01	9 NCT06556368 NCT06635148 NCT06864988 NCT07064759	90
17	Mid Atlantic Retina Philadelphia, United States · 10 spellings merged	24 16 completed, 8 terminated	NCT04567303 NCT04770545 NCT05536297 6 trials with titles NCT04567303 Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration completed 2026-08-25 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT05536297 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy completed 2025-04-10 NCT03846193 FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD terminated 2024-06-25 Stop reason on the record: “The study was terminated due to the interim analysis demonstrating lack of treatment efficacy.” NCT04566445 HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 terminated 2024-06-10 Stop reason on the record: “Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns.” NCT04437368 EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 terminated 2024-04-05 Stop reason on the record: “Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns.”	2026-08-25	8 NCT06541704 NCT03683251 NCT02286089 NCT05626114	88
18	Florida Eye Associates Melbourne, United States · 3 spellings merged	22 17 completed, 5 terminated	NCT06116890 NCT05536297 NCT06011798 6 trials with titles NCT06116890 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration completed 2026-07-01 NCT05536297 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy completed 2025-04-10 NCT06011798 Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) completed 2025-04-08 NCT04777201 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration completed 2024-09-03 NCT04423718 Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye completed 2024-08-07 NCT04611152 A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) terminated 2023-08-31 Stop reason on the record: “Study did not meet primary endpoint”	2026-07-01	2 NCT03683251 NCT05197270	88
19	Georgia Retina PC Marietta, United States · 5 spellings merged	22 17 completed, 5 terminated	NCT05811351 NCT04770545 NCT04777201 6 trials with titles NCT05811351 A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) completed 2026-02-23 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT04777201 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration completed 2024-09-03 NCT05891548 Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration completed 2024-08-20 NCT04566445 HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 terminated 2024-06-10 Stop reason on the record: “Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns.” NCT04603937 A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) terminated 2023-08-31 Stop reason on the record: “Study did not meet primary endpoint”	2026-02-23	6 NCT06541704 NCT06635148 NCT03683251 NCT06864988	91
20	Retina Northwest Portland, United States · 7 spellings merged	21 18 completed, 3 terminated	NCT05230537 NCT04770545 NCT05536297 6 trials with titles NCT05230537 A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration completed 2026-09-30 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT05536297 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy completed 2025-04-10 NCT04777201 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration completed 2024-09-03 NCT04423718 Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye completed 2024-08-07 NCT04611152 A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) terminated 2023-08-31 Stop reason on the record: “Study did not meet primary endpoint”	2026-09-30	7 NCT06087458 NCT06556368 NCT06541704 NCT03683251	92
21	Retinal Consultants Medical Group Sacramento, United States · 12 spellings merged	21 17 completed, 4 terminated	NCT05230537 NCT05839041 NCT05893537 6 trials with titles NCT05230537 A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration completed 2026-09-30 NCT05839041 A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) completed 2026-02-18 NCT05893537 Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). terminated 2025-03-28 Stop reason on the record: “The trial was closed as part of a strategic business decision.” NCT05891548 Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration completed 2024-08-20 NCT04603937 A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) terminated 2023-08-31 Stop reason on the record: “Study did not meet primary endpoint” NCT04435366 A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) completed 2023-08-22	2026-09-30	21 NCT06087458 NCT06556368 NCT06541704 NCT07705555	94
22	Texas Retina Associates Dallas, United States · 7 spellings merged	20 15 completed, 5 terminated	NCT06664502 NCT06704009 NCT05811351 6 trials with titles NCT06664502 A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration completed 2026-08-11 NCT06704009 NT-101 Topical Ophthalmic Solution in Patients With Wet AMD completed 2026-05-06 NCT05811351 A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) completed 2026-02-23 NCT05839041 A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) completed 2026-02-18 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT04777201 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration completed 2024-09-03	2026-08-11	14 NCT06541704 NCT06635148 NCT07205887 NCT07215234	88
23	California Retina Consultants Bakersfield, United States · 7 spellings merged	20 15 completed, 5 terminated	NCT07214740 NCT04770545 NCT06011798 6 trials with titles NCT07214740 Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe completed 2025-12-12 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT06011798 Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) completed 2025-04-08 NCT05891548 Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration completed 2024-08-20 NCT04857996 Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD) completed 2023-04-06 NCT04964089 A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) completed 2023-04-06	2025-12-12	14 NCT03683251 NCT06864988 NCT07606365 NCT06491914	90
24	California Retina Consultants Santa Barbara, United States · 7 spellings merged	19 15 completed, 4 terminated	NCT05230537 NCT05839041 NCT04770545 6 trials with titles NCT05230537 A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration completed 2026-09-30 NCT05839041 A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) completed 2026-02-18 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT04777201 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration completed 2024-09-03 NCT04832724 RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) completed 2024-03-18 NCT04607148 A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration terminated 2022-11-14 Stop reason on the record: “The benefit to risk balance did not support further treatment with galegenimab (FHTR2163).”	2026-09-30	7 NCT03683251 NCT06864988 NCT07614776 NCT07441642	92
25	Charles Retina Institute Germantown, United States · 2 spellings merged	19 15 completed, 4 terminated	NCT05230537 NCT04567303 NCT06116890 6 trials with titles NCT05230537 A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration completed 2026-09-30 NCT04567303 Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration completed 2026-08-25 NCT06116890 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration completed 2026-07-01 NCT05811351 A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) completed 2026-02-23 NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD completed 2025-09-05 NCT04777201 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration completed 2024-09-03	2026-09-30	7 NCT06556368 NCT03683251 NCT07440225 NCT06668064	89

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Age-related macular degeneration: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Robert W Snyder Robert Snyder, MD, PhD, PC	4	NCT03451500 NCT03197493 NCT03023059 NCT03022318	No paper matched at High or Medium confidence
2	Youxin Chen Peking Union Medical College	2	NCT05141994 NCT05345236	PMID 42819474 iMeta, 2026 · High match
3	Se Joon Woo Seoul National University Bundang Hospital, South Korea	2	NCT04450329 NCT03150589	PMID 42658802 PloS one, 2026 · High match PMID 42286041 Scientific reports, 2026 · High match PMID 41927600 Scientific reports, 2026 · High match
4	Douglas A Jabs Center for Clinical Trials and Evidence Synthesis, JHU, Baltimore, MD	2	NCT02623426 NCT02374060	No paper matched at High or Medium confidence
5	Jeffrey Heier Ophthalmic Consultants of Boston	2	NCT03066258 NCT02462889	PMID 42501959 American journal of ophthalmology, 2026 · High match PMID 42132121 Current medical research and opinion, 2026 · High match
6	Jason Hsu Wills Eye	2	NCT03034772 NCT02571972	PMID 42812627 Journal of vitreoretinal diseases, 2026 · High match PMID 42518877 Journal of vitreoretinal diseases, 2026 · High match PMID 41244030 Journal of vitreoretinal diseases, 2026 · High match
7	Raj K Maturi Raj K. Maturi, MD, PC	2	NCT02732899 NCT02357342	No paper matched at High or Medium confidence
8	Dr. Niaz Abdur Rahman Managing Director, Bangladesh Eye Hospital & Institute	1	NCT06305416	No paper matched at High or Medium confidence
9	Kun Liu Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	1	NCT05456828	PMID 42171393 Journal of global health, 2026 · High match PMID 41117141 Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026 · High match PMID 41023746 Lipids in health and disease, 2025 · High match
10	Duaa J Kadhim University of Baghdad	1	NCT07093385	No paper matched at High or Medium confidence

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.